Mérieux Equity Partners is a prominent European investment firm based in Lyon, France, focusing on the healthcare and nutrition sectors. Established in 2009, the firm manages over €1.5 billion in assets through various funds dedicated to venture capital, growth, and buyout investments. It supports innovative medical solutions and health products, investing in companies ranging from early-stage startups to established leaders primarily in Europe and North America. The firm operates through multiple platforms, including a Venture Capital Platform that targets seed to Series B funding for diagnostic and therapeutic innovations, and a Growth/Buyout Platform that invests in more mature companies. Additionally, Mérieux Equity Partners has a Venture Studio, M2care, which co-develops early-stage HealthTech projects. The company partners closely with entrepreneurs and management teams, providing not only capital but also operational expertise and access to a broad network in the healthcare industry. With a dedicated team of professionals, Mérieux Equity Partners is committed to fostering growth and innovation in the healthcare and nutrition sectors.
我們正在追蹤 Merieux Equity Partners 的市場擴張
Merieux Equity Partners 的國際擴張與競爭對手的比較
Merieux Equity Partners你長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
 Merieux Equity Partners你 | 0 | 0 | — | 0 | 0 |
Marketing & Communication Specialist
查看招聘Lyon, Auvergne-Rhône-Alpes, France · 上年
無進行中的廣告活動
註冊以追蹤此公司，並在發生變化時第一時間獲得提醒。
諾基因從Mérieux Equity Partners收購Theravia，加強其罕見病藥物組合和在歐洲特種藥品市場的地位。
Ceva動物健康重組資本，投資者信心renewed，管理層保持控制權和獨立性，同時歡迎新投資者支持全球增長和創新。
DeepUll完成5000萬歐元C輪融資,用於快速敗血症診斷。由Columbus、Panakès、Mérieux領投。UllCORE系統可在1小時內檢測病原體。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 Merieux Equity Partners 業務、市場及增長訊號的快速解答。
